Bacteriology

NovoBiome and INRAE, a new Associated Partner Laboratory on human gut microbiota

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Microbiology, Genomics, Environmental microbiology, Microbiomes, Bacteriology, Metagenomics, Microbiota, Human microbiome, DNA sequencing, Omics

INRAEs collaboration with NovoBiome is the second research agreement of its type, aimed at accelerating the development of innovations.

Key Points: 
  • INRAEs collaboration with NovoBiome is the second research agreement of its type, aimed at accelerating the development of innovations.
  • Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said: Next-generation sequencing and quantitative metagenomics approaches have enabled the reconstruction of whole genomic entities.
  • In addition, functional metagenomics has allowed access to the potential of bacterial genes of the whole gut microbiota.
  • NovoBiome is developing a proprietary platform, NovoSift, that rationally identifies Live Biotherapeutics based on a deep understanding of functions and mechanisms.

Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology

Retrieved on: 
Wednesday, June 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health sciences, Life sciences, Health, Environmental microbiology, Pharmaceutical industry, Bacteriology, Microbiomes, Clinical research, Clinical trial, Gut microbiota

Clinical trials are due to begin in 2022.

Key Points: 
  • Clinical trials are due to begin in 2022.
  • However clinical translation of this ground-breaking discovery has been hampered by large inconsistencies between studies in the intestinal bacteria associated with anti-PD1 efficacy.
  • The Microbiotica platform is unrivalled in the comprehensiveness and precision by which it can profile the microbiome of patients.
  • The Live Bacterial Therapeutic, MB097, arising from this signature, aims to tap into this predictive signature of ICI therapy response.

Mia Syn, RDN Partners with Digestive Health Company PanTheryx

Retrieved on: 
Wednesday, June 23, 2021
Retail, Health, Fitness & Nutrition, Specialty, General Health, Food, Beverage, Biotechnology, Medical specialties, Bacteriology, Digestive system, Branches of biology, Medicine, Breast milk, Colostrum, Milk, Probiotic, Dietary supplement, Biotic

PanTheryx, an integrative digestive and immune health company, today announced its partnership with Mia Syn, MS, RDN as the companys new nutrition advisor for its TruBiotics brand of probiotics and its Lifes First Naturals brand of colostrum based dietary supplements.

Key Points: 
  • PanTheryx, an integrative digestive and immune health company, today announced its partnership with Mia Syn, MS, RDN as the companys new nutrition advisor for its TruBiotics brand of probiotics and its Lifes First Naturals brand of colostrum based dietary supplements.
  • We are pleased to have Mia Syn join our effort in growing awareness of the numerous digestive and immune health benefits of probiotics and colostrum among health-conscious adults, said Wes Parris, president and CEO, PanTheryx.
  • TruBiotics is a high-quality probiotic supplement that works naturally to support digestive and immune health in adults.
  • PanTheryx is a nutrition and biotechnology company committed to the broad commercialization of health and wellness solutions for the global human and animal health markets.

DERMALA, A Consumer Dermatology Company, Announces Issuance of A New U.S. Patent Covering Human Microbiome to Treat and Prevent Acne

Retrieved on: 
Wednesday, June 23, 2021
Microbiomes, Branches of biology, Bacteriology, Microbiology, Environmental microbiology, Dutch inventions, Microscopy, Microbiome, Human microbiome, Acne, Human Microbiome Project, Richard Gallo

This patent covers using the human microbiome to treat and prevent acne.Acneis the eighthmost prevalent disease worldwide and the most common skin condition.

Key Points: 
  • This patent covers using the human microbiome to treat and prevent acne.Acneis the eighthmost prevalent disease worldwide and the most common skin condition.
  • DERMALA's patented technology uses novel, human microbiome-derived postbiotics, metabolites derived from beneficial bacteria in the human microbiome, that inhibit acne-causingC.
  • Using the human microbiome to treat skin conditions associated with microbiome imbalances makes great scientific sense.
  • DERMALA, Inc. is a consumer dermatology company leveraging a scientific understanding of the human microbiome and data analytics to develop novel solutions for acne and other skin conditions.

100 Billion Live Probiotics in a Bottle: TCI JAPAN Launched its Breakthrough, SCIENCE OF PROBIOTICS, After 20 Years of Research

Retrieved on: 
Wednesday, June 23, 2021
Food and drink, Branches of biology, Biology, Food science, Bacteriology, Fermentation, Brewing, Mycology, Probiotic, Lactic acid bacteria, Lactic acid, Lactic

Fortunately, after 20 years of research and development, SCIENCE OF PROBIOTICS by TCI JAPAN finally broke through the existing limitations and found new ways to create innovative probiotic beverages.

Key Points: 
  • Fortunately, after 20 years of research and development, SCIENCE OF PROBIOTICS by TCI JAPAN finally broke through the existing limitations and found new ways to create innovative probiotic beverages.
  • Lactic acid bacteria refer to a group of bacteria that can convert sugars (such as glucose, lactose, etc.)
  • Lactic acid bacteria are widely used in the manufacturing of fermented foods, such as kimchi, soy sauce and wine.
  • Lactic acid bacteria have been consumed for a wide range of health benefits in Japan for years.

Global Prebiotic Ingredients Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Seniors, Packaging, Fitness & Nutrition, Manufacturing, Food, Beverage, Health, Consumer, Pharmaceutical, Retail, Bacteriology, Digestive system, Branches of biology, Prebiotic, Dietary supplement, Gut microbiota, Biology

Moreover, key players are also actively offering prebiotic supplements, as maintenance of a healthy gut is increasingly becoming important among consumers.

Key Points: 
  • Moreover, key players are also actively offering prebiotic supplements, as maintenance of a healthy gut is increasingly becoming important among consumers.
  • According to the international study by Beneo Inc., 42% of consumers are very or extremely interested in gut microbiome.
  • Such factors are escalating the application of prebiotic ingredients in various food and beverage applications.
  • Healthcare professionals across the region recommend dietary supplements containing prebiotic ingredients to their patients, to combat health challenges.

KeVita and Amber Riley Team Up to Celebrate the Summer of Self-Care with New Prebiotic Shots

Retrieved on: 
Tuesday, June 22, 2021
Food and drink, Medical specialties, Bacteriology, Digestive system, Fermented drinks, Fermented dairy products, Branches of biology, Prebiotic, Tibicos, Filmjölk, Probiotic, Kefir

"I've been a long-time fan of KeVita, especially their Lemon Ginger Sparkling Probiotic Drink, so I was excited to be one of the first to try the new Prebiotic Shots line.

Key Points: 
  • "I've been a long-time fan of KeVita, especially their Lemon Ginger Sparkling Probiotic Drink, so I was excited to be one of the first to try the new Prebiotic Shots line.
  • Between filming, working out and spending time with my family and friends, these convenient shots fit perfectly into my schedule.
  • KeVita's organic Prebiotic Shots are fermented with water kefir culture and offer three grams of prebiotic fiber.
  • KeVita Prebiotic Shots begin to roll out this summer at mass grocery, drug, convenience and specialty food stores nationwide.

Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

Retrieved on: 
Friday, June 18, 2021
Moraxellaceae, Bacterial diseases, Medical specialties, Chemical compounds, Bacteriology, Antibiotics, Acinetobacter baumannii, Gram-negative bacteria, Pathogenic bacteria, Acinetobacter, Pseudomonas infection, Zoliflodacin

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24.

Key Points: 
  • WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24.
  • Entasis will present 11 posters with one oral presentation highlighting ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against Pseudomonas aeruginosa.
  • Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
  • For more information, visit www.entasistx.com.

ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum

Retrieved on: 
Thursday, June 17, 2021
Bacteriology, Epidemiology, Infection, Bacteria, Microorganism, Units of time, 2nd millennium, Branches of biology, Microbiology

ContraFect will deliver two oral presentations and present three posters, available on the World Microbe Forum website to registered attendees.

Key Points: 
  • ContraFect will deliver two oral presentations and present three posters, available on the World Microbe Forum website to registered attendees.
  • Following the meeting, the presentation posters will be available on the ContraFect website .
  • CF-370 has been engineered to bypass the outer membrane of the bacteria and to enable potent activity in human serum.
  • Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases.

New Cleveland Clinic Research Identifies Link Between Gut Microbes and Stroke

Retrieved on: 
Wednesday, June 16, 2021
Microbiomes, Chemical substances, Medical specialties, Branches of biology, Cleveland Clinic, Fairfax, Cleveland, Bacteriology, Environmental microbiology, Trimethylamine N-oxide, Gut microbiota, Microbiome

CLEVELAND, June 16, 2021 /PRNewswire/ --New findings from Cleveland Clinic researchers show for the first time that the gut microbiome impacts stroke severity and functional impairment following stroke.

Key Points: 
  • CLEVELAND, June 16, 2021 /PRNewswire/ --New findings from Cleveland Clinic researchers show for the first time that the gut microbiome impacts stroke severity and functional impairment following stroke.
  • The research was led by Weifei Zhu, Ph.D., and Stanley Hazen, M.D., Ph.D ., of Cleveland Clinic's Lerner Research Institute.
  • "Remarkably, simply transplanting gut microbes capable of making TMAO was enough to cause a profound change in stroke severity."
  • Cleveland Clinic now in its centennial year is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.